Ahmed Alanazi, Head of Hematology/Oncology Clinical Pharmacy Section at King Fahad Medical City – KFMCK, shared a post on X:
“Are we heading toward new mechanisms of fighting breast cancer
Pumitamig (Bispecific antibody dual PD-L1/VEGF-A blockade) combined with BNT325(TRPO2i ADC) in first line advanced/metastatic TNBC
Impressive result as we know that anti Pd-1 plus Trop2 ADC is standard of care in mTNBC
- DCR 96.7%
- ORR 76.7%
- mPFS NR
Although too early to judge with Phase1/2 and small sample size with short F/Up.”
More posts featuring Ahmed Alanazi.
